Biology for Treatments of Drug-Resistant Cancers in Children
- Thematic(s)
- Genetics / Genomics, Immuno-oncology, Precision Medicine, Pediatric Oncology, Innovative Therapies
- Manager(s)
- Birgit Geoerger
- Institutional connection
-
Gustave Roussy, Inserm, Paris-Saclay University
Summary
Advanced cancers are the leading cause of death among children, adolescents, and young adults due to primary and secondary resistance to current treatments. The team founded MOSCATO-01-ped, MAPPYACTS, PFMG2025/MAPPYACTS2, AcSé-ESMART, pediatric precision medicine programs and is developing new therapeutic strategies for advanced cancers through the expansion of molecular profiling trials, biological characterization, the study of tumor resistance and immune escape mechanisms—with a particular focus on osteosarcoma—the identification and evaluation of new therapies, and biology-driven clinical trials to validate therapeutic concepts.
Our research benefits from exceptional access to primary tumor samples accompanied by comprehensive clinical annotations and generated multi-omic data, including whole-exome and whole-transcriptome sequencing, single-cell analysis, the national Boost-DataS (EDS) database, patient-derived xenografts and organoids, as well as patients treated with experimental targeted therapies.
To translate biological discoveries into clinical applications, we are pursuing two main lines of research:
-
Identifying therapeutic targets and studying resistance mechanisms in advanced pediatric cancers, with a focus on the biological mechanisms involved in cancer resistance: namely the immune landscape and response mechanisms, DNA repair deficiencies, and metabolism. An in-depth study focuses on osteosarcoma, a disease that is difficult to treat due to its genetic complexity, chromosomal rearrangements, and microenvironment, using single-cell or spatial transcriptomics/proteomics approaches to map tumor plasticity and locate resistant niches.
-
Translate biological discoveries into patient care through the development of biology-driven clinical trials and the identification of biomarkers (e.g., AcSé-ESMART; FOSTER).
Given the underlying complexity of tumors and their hosts, as well as the limitations of preclinical models, we believe that these interactive translational trials are essential to achieving a breakthrough in the implementation of biologically targeted strategies, leading to effective treatments for children with cancer.
Team members
-
Birgit GEOERGER - Team Leader
Hospital Physician, Gustave Roussy
ANNEREAU, Maxime
Hospital Physician, Gustave Roussy
AUDINOT Baptiste
Ph.D. Candidate, Paris-Saclay University
BERLANGA Pablo
Hospital Physician, Gustave Roussy
BERTRAND Mathilde
Design Engineer or equivalent, Gustave Roussy
BLUTEAU Dominique
Associate Professor, Other
CARDON Melis
Research Engineer or equivalent, Gustave Roussy
CHANTOISEAU Margaux
Ph.D. Candidate, Paris-Saclay University
DANGLIOLO Silvana Beatriz
Engineering Assistant or equivalent, Gustave Roussy
FROMIGUÉ Olivia
Research Associate or equivalent, Inserm
GAGNEUX Florian
Engineering Assistant or equivalent, Gustave Roussy
GASPAR Nathalie
Hospital Physician, Gustave Roussy
GAUTHIER Nina
Hospital Physician, Gustave Roussy
Khneisser Pierre
Hospital Physician, Gustave Roussy
KSONTINI Amal
Ph.D. candidate, Paris-Saclay University
LUCCHINI Blandine
Ph.D. candidate, Paris-Saclay University
MARCHAIS Antonin
Researcher and equivalent positions, Inserm
MARQUES DA COSTA Maria Eugénia
Research Engineer or equivalent, Gustave Roussy
MELTZ Capucine
Research Technician or equivalent, Gustave Roussy
MOQUIN-BEAUDRY Gaël
Postdoctoral Fellow, Gustave Roussy
PIO Luca
Hospital Physician, Other
SALMON Jérôme
Research Engineer or Equivalent, Gustave Roussy
THUILLIEZ Corentin
Research Technician or Equivalent, Gustave Roussy
Key publications
Other scientific productions
Contacts
- Phone
- Manager: 01.42.11.23.86